Duiverman E J, Brackel H J, Merkus P J, Rottier B L, Brand P L
Academisch Ziekenhuis, Beatrix Kinderkliniek, afd. Kindergeneeskunde, sectie Kinderlongziekten, Postbus 30.001, 9700 RB Groningen.
Ned Tijdschr Geneeskd. 2003 Sep 27;147(39):1909-13.
The second revision of the guidelines for the treatment of asthma in children is largely based on the evidence of comparative studies. Short-acting beta 2-sympathicomimetics are the medication of choice for acute exacerbations and should therefore be prescribed to each patient. Inhaled corticosteroids (ICS) are the medication of choice for maintenance treatment. Starting with a high dose of ICS which is then reduced to a lower but effective level on the basis of the complaints (step-down approach) is no longer recommended, as this strategy is not more effective than a constant dosage schedule. If asthmatic symptoms persist despite ICS maintenance treatment then 3 therapeutic options are available in the following order: doubling the ICS dose, the addition of a long-acting beta 2-sympathicomimetic, and the addition of a leukotriene receptor antagonist.
儿童哮喘治疗指南的第二次修订主要基于对比研究的证据。短效β2-肾上腺素能激动剂是急性加重期的首选药物,因此应给每位患者开具此类药物。吸入性糖皮质激素(ICS)是维持治疗的首选药物。不再推荐开始使用高剂量ICS然后根据症状降至较低但有效的水平(逐步减量法),因为该策略并不比持续给药方案更有效。如果在ICS维持治疗后哮喘症状仍持续存在,则按以下顺序有三种治疗选择:将ICS剂量加倍、加用长效β2-肾上腺素能激动剂以及加用白三烯受体拮抗剂。